{"title":"Abstract IA05: Research addressing cervical cancer disparities: Progress, challenges, and opportunities","authors":"E. Paskett","doi":"10.1158/1538-7755.DISP17-IA05","DOIUrl":null,"url":null,"abstract":"In 2007, disparities in cervical cancer incidence and mortality were evident among black vs white women, Hispanic vs non-Hispanic women, and rural vs non-rural women. Reasons for these disparities include lack of Pap testing, inappropriate follow-up after an abnormal test, and high rates of infection with high-risk human papillomavirus (HPV). In 2017, these disparities still exist. While early detection tests for cervical cancer have been available since the late 1950s, prevention of cervical cancer began with the identification of HPV as a necessary cause for cervical cancer and the subsequent development, testing, and approval of the HPV vaccine in 2006 for girls and 2011 for boys. Uptake of the vaccine in age-eligible girls and boys has been slow in the US, with better uptake--and a complementary reduction in HPV infection and preinvasive cervical abnormalities--in other countries such as Australia, the United Kingdom, and Rwanda. Screening guidelines have been updated to focus on more appropriate age and cotesting with HPV cytology. Challenges are apparent in assuring that rates of uptake of the vaccine series approach the 80% threshold set by the CDC for all populations. Moreover, rates of appropriate screening--including the new guidelines for cotesting--are challenging to maintain, as there is confusion regarding these guidelines among both patients and providers. Appropriate follow-up after an abnormal Pap test remains a problem, with lower follow-up among minority, low-income, and rural populations. There are many opportunities for increasing the uptake of the HPV vaccine series, appropriate screening, and prompt and proper follow-up of abnormalities in populations experiencing disparities. Several areas of investigation show promise and deserve further exploration. These include: one vs two/three doses of the HPV vaccine; HPV self-testing strategies to increase adherence to screening; and use of “see and treat” strategies to assure follow-up and treatment of cervical abnormalities in low-resource settings. In addition, creative and culturally appropriate multilevel intervention approaches should be tested to increase adherence in populations suffering from disparities. Strategies to increase adherence to HPV vaccine series, screening, and follow-up recommendations can make a significant reduction in cervical cancer incidence and mortality disparities. Citation Format: Electra D. Paskett. Research addressing cervical cancer disparities: Progress, challenges, and opportunities [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr IA05.","PeriodicalId":300297,"journal":{"name":"Cancer Disparities Research: 10 Years of Progress and Promise","volume":"39 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Disparities Research: 10 Years of Progress and Promise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7755.DISP17-IA05","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In 2007, disparities in cervical cancer incidence and mortality were evident among black vs white women, Hispanic vs non-Hispanic women, and rural vs non-rural women. Reasons for these disparities include lack of Pap testing, inappropriate follow-up after an abnormal test, and high rates of infection with high-risk human papillomavirus (HPV). In 2017, these disparities still exist. While early detection tests for cervical cancer have been available since the late 1950s, prevention of cervical cancer began with the identification of HPV as a necessary cause for cervical cancer and the subsequent development, testing, and approval of the HPV vaccine in 2006 for girls and 2011 for boys. Uptake of the vaccine in age-eligible girls and boys has been slow in the US, with better uptake--and a complementary reduction in HPV infection and preinvasive cervical abnormalities--in other countries such as Australia, the United Kingdom, and Rwanda. Screening guidelines have been updated to focus on more appropriate age and cotesting with HPV cytology. Challenges are apparent in assuring that rates of uptake of the vaccine series approach the 80% threshold set by the CDC for all populations. Moreover, rates of appropriate screening--including the new guidelines for cotesting--are challenging to maintain, as there is confusion regarding these guidelines among both patients and providers. Appropriate follow-up after an abnormal Pap test remains a problem, with lower follow-up among minority, low-income, and rural populations. There are many opportunities for increasing the uptake of the HPV vaccine series, appropriate screening, and prompt and proper follow-up of abnormalities in populations experiencing disparities. Several areas of investigation show promise and deserve further exploration. These include: one vs two/three doses of the HPV vaccine; HPV self-testing strategies to increase adherence to screening; and use of “see and treat” strategies to assure follow-up and treatment of cervical abnormalities in low-resource settings. In addition, creative and culturally appropriate multilevel intervention approaches should be tested to increase adherence in populations suffering from disparities. Strategies to increase adherence to HPV vaccine series, screening, and follow-up recommendations can make a significant reduction in cervical cancer incidence and mortality disparities. Citation Format: Electra D. Paskett. Research addressing cervical cancer disparities: Progress, challenges, and opportunities [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr IA05.
2007年,宫颈癌发病率和死亡率在黑人妇女与白人妇女、西班牙裔妇女与非西班牙裔妇女、农村妇女与非农村妇女之间存在明显差异。造成这些差异的原因包括缺乏巴氏涂片检查,异常检查后不适当的随访,以及高危人乳头瘤病毒(HPV)的高感染率。2017年,这些差距仍然存在。虽然早在20世纪50年代末就可以进行宫颈癌的早期检测,但宫颈癌的预防始于确定HPV是宫颈癌的必要原因,随后在2006年为女孩和2011年为男孩开发、测试和批准了HPV疫苗。在美国,符合年龄条件的女孩和男孩接种疫苗的速度很慢,而在澳大利亚、英国和卢旺达等其他国家,接种疫苗的速度更快,HPV感染和侵袭性宫颈异常的发生率也相应降低。筛查指南已更新,重点放在更合适的年龄和与HPV细胞学共同检测。在确保疫苗系列接种率接近疾病预防控制中心为所有人群设定的80%阈值方面,挑战是显而易见的。此外,适当的筛查率——包括新的共同检测指南——很难维持,因为患者和提供者对这些指南都存在混淆。异常巴氏涂片检查后的适当随访仍然是一个问题,少数民族、低收入和农村人口的随访率较低。在经历差异的人群中,有许多机会可以增加HPV疫苗系列的吸收,进行适当的筛查,并对异常情况进行及时和适当的随访。几个调查领域显示出希望,值得进一步探索。这些措施包括:一剂vs两剂/三剂HPV疫苗;人乳头瘤病毒自我检测策略,以提高对筛查的依从性;在资源匮乏的环境中,使用“看到并治疗”策略确保对宫颈异常进行随访和治疗。此外,应试验创造性和文化上适当的多层次干预方法,以增加遭受差异的人群的依从性。加强遵守HPV疫苗系列、筛查和随访建议的策略可以显著减少宫颈癌发病率和死亡率差异。引文格式:Electra D. Paskett。宫颈癌差异研究:进展、挑战和机遇[摘要]。见:第十届AACR会议论文集:种族/少数民族和医疗服务不足人群的癌症健康差异科学;2017年9月25-28日;亚特兰大,乔治亚州。费城(PA): AACR;癌症流行病学与生物标志物杂志,2018;27(7增刊):摘要nr IA05。